Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Pulmonary Medicine

Background:

• The 4-month rifapentine-moxifloxacin regimen shows promise for treating drug-susceptible pulmonary tuberculosis.
• Understanding factors influencing treatment outcomes is crucial for optimizing patient care.

Purpose of the Study:

• To analyze demographic, clinical, microbiologic, radiographic, and pharmacokinetic data from the TBTC Study 31/ACTG A5349 trial.
• To identify risk factors for unfavorable outcomes and adverse events associated with the rifapentine-moxifloxacin regimen.
• To develop a risk stratification model for classifying tuberculosis (TB) disease phenotypes.

Main Methods:

• Phase 3 randomized controlled trial (TBTC Study 31/ACTG A5349).
• Analysis of efficacy (12-month disease-free survival) and safety (Grade 3+ adverse events).
• Multivariable analysis of demographic, clinical, microbiologic, radiographic, and pharmacokinetic data to identify risk factors.

Main Results:

• Low rifapentine exposure was the strongest predictor of unfavorable tuberculosis outcomes (HR 0.65 per 100 µg·h/mL increase).
• Higher baseline disease severity (Xpert MTB/RIF cycle threshold, extent of disease on chest radiography) also predicted unfavorable outcomes.
• No safety concerns were identified with high rifapentine exposures.

Conclusions:

• A risk stratification model categorizes TB into easier-, moderately-harder, or harder-to-treat phenotypes.
• Easier-to-treat TB patients may benefit from treatment shortening.
• Harder-to-treat TB patients might require higher doses or longer treatment durations.